- Neogen saw organic revenue growth reaccelerate into the double-digits in the last quarter, helped by both one-off events (the pandemic and ASF), and longer-term opportunities like companion animal diagnostics.
- Management is targeting larger M&A, but deal competition has been intense and there could be some risk to market expectations for acquired growth.
- Neogen serves two attractive markets with solid long-term GDP-plus growth potential, but the valuation has long been challenging and remains so today.
For further details see:
Neogen Seeing Reacceleration In Revenue And Large, Growing Addressable Markets